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Abstract
Current anti-inflammatory strategies for the treatment of pulmonary disease in cystic fibrosis (CF) are limited; thus, there is
continued interest in identifying additional molecular targets for therapeutic intervention. Given the emerging role of
sphingolipids (SLs) in various respiratory disorders, including CF, drugs that selectively target the enzymes associated with
SL metabolism are under development. Miglustat, a well-characterized iminosugar-based inhibitor of b-glucosidase 2
(GBA2), has shown promise in CF treatment because it reduces the inflammatory response to infection by P. aeruginosa and
restores F508del-CFTR chloride channel activity. This study aimed to probe the molecular basis for the anti-inflammatory
activity of miglustat by examining specifically the role of GBA2 following the infection of CF bronchial epithelial cells by P.
aeruginosa. We also report the anti-inflammatory activity of another potent inhibitor of GBA2 activity, namely N-(5-
adamantane-1-yl-methoxy)pentyl)-deoxynojirimycin (Genz-529648). In CF bronchial cells, inhibition of GBA2 by miglustat or
Genz-529648 significantly reduced the induction of IL-8 mRNA levels and protein release following infection by P.
aeruginosa. Hence, the present data demonstrate that the anti-inflammatory effects of miglustat and Genz-529648 are likely
exerted through inhibition of GBA2.
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Introduction
Cystic fibrosis (CF) lung disease is characterized by progressive
chronic infection and inflammation of the airways. The prolonged
airway inflammation is an important aspect of the obstructive lung
disease noted in CF patients. Resultant progressive remodeling
leads to irreversible damage and fibrosis, which is a major cause of
mortality in patients [1]. Significant efforts have been invested into
developing therapies that address the underlying basis of CF. For
example, recent efforts to identify small-molecule drugs that target
a mutant CF transmembrane conductance regulator (CFTR) led
to the successful development of a potentiator (Kalydeco) for
patients who harbor the mutant G551D-CFTR [2]. Moreover,
phase 3 clinical trials of Kalydeco in combination with the
corrector lumacaftor for people with two copies of the F508del-
CFTR mutation showed significant improvements in lung function
and other key measures of the disease (http://www.cff.org/about
CFFoundation/NewsEvents/2014NEWSArchive/6-24-Vertex
Phase-3-Results_Lumacaftor_Ibvacaftor.cfm). However, despite
these very encouranging results, adjuvant therapies that abate
the decline in pulmonary function in other patients are still
needed. Examples include the potential deployment of new
antibiotics, anti-mucolytic and anti-inflammatory drugs [3]. To
date, the only non-steroidal anti-inflammatory agent that has been
shown to be beneficial in CF patients is ibuprofen; however, its use
can be associated with severe adverse effects, such as gastrointes-
tinal bleeding [4]. Hence, the identification and development of
novel and more potent anti-inflammatory drugs for CF airway
disease remains a priority. The chemokine IL-8 is abundantly
expressed at sites of chronic inflammation and appears to play a
major role in driving the formation of neutrophil (PMN)-rich
exudates in the lungs of CF patients [5–8]; thus its reduction is a
key therapeutic goal in CF.
Sphingolipids (SLs) are a large group of lipids that are thought
to modulate the pathophysiology of several respiratory disorders,
including CF [9–11]. Ceramide, the central hub of SL metabo-
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lism, is generated by de novo synthesis or hydrolysis of complex
SLs, such as sphingomyelin (SM) by acid sphingomyelinase (ASM)
and glucosylceramide (GlcCer) by glucocerebrosidases [12].
Ceramide plays an important role in the infection by P.
aeruginosa by reorganizing lipid rafts on cellular membranes into
larger signaling platforms, which is a feature conducive to
internalizing bacteria, inducing apoptosis and regulating the
cytokine response [13]. Controversial findings on the association
between abnormalities in SL metabolism and inflammation in CF
have been reported. For example, ceramide has been identified as
a key regulator of inflammation in CF airways in different
CFTR-/- mouse models [14]. In contrast, decreased ceramide
levels have been demonstrated in CFTR KO mice [15], and no
significant difference has been found in basal ceramide levels in
CFTR KO lung homogenates compared to wild type mice [16].
The possible explanation for this discrepancy appears to be the
special diet required for the survival of CFTR KO mice, which
severely affects the concentration of SLs [14]. Interestingly, an
accumulation of ceramide, which has been directly correlated with
neutrophilic lung inflammation, has been demonstrated in the
lower airway of CF patients [17]. These findings suggest that the
CF pathophysiology associated with infection by P. aeruginosa
can be corrected, in part, by modulating ceramide levels to their
normal physiological range, independent of the conflicting results
obtained in different CF models. To date, there is some evidence
that supports pharmacological interventions in SL metabolism as
therapeutic agents for CF lung disease [14–21].
Given the emerging importance of SLs in respiratory disorders,
novel drugs that selectively target different enzymes involved in SL
metabolism are under development. Recently developed iminosu-
gar-based inhibitors of GBA2 are of particular interest because of
their good oral bioavailability and specific immune modulatory
and chaperoning activities [22]. A well-characterized inhibitor is
miglustat (N-butyldeoxynojirimycin, NB-DNJ), which is FDA-
approved and EMA-designated for use in Europe and the USA for
the treatment of type I Gaucher and other SL storage diseases. We
previously demonstrated that miglustat exhibits an anti-inflamma-
tory effect in vitro and in vivo by reducing P. aeruginosa induced
immunoreactive ceramide levels [20,23]. Moreover, miglustat can
restore F508del-CFTR chloride channel activity in respiratory and
pancreatic cells in vitro [24,25] and in CF mice [26]. However, a
recent clinical trial in CF patients did not provide evidence of
efficacy, which may be related to the intra-individual variability of
nasal potential difference (NPD) measurements or the short
duration of exposure [27]. Nevertheless, a drug that is able to
correct both the CF channel defect and reduce the inflammatory
response is of interest and warrants further attention. Miglustat
inhibits the enzyme ceramide glucosyl-transferase (GlcCerT),
which catalyzes the first step in the glycosphingolipid biosynthetic
pathway [28] with IC50 values in the low micromolar range. It
also inhibits the activities of two different GlcCer degrading
enzymes, glucocerebrosidase (GBA1) and the non-lysosomal b-
glucosidase 2 (GBA2), with IC50 values in the high micromolar
and nanomolar range, respectively [29,30]. In addition, it is also a
potent inhibitor of a-glucosidase [31]. Therefore, miglustat could
affect the host response to P. aeruginosa through one or more of
these SL metabolism pathways. The galactose analog of miglustat,
N-butyldeoxygalactonojirimycin (NB-DGJ), also inhibits GlcCerT
and GBA2, whereas its effect on GBA1 is less clear [30,32,33].
Similar to miglustat, NB-DGJ produces an anti-inflammatory
effect in bronchial epithelial cells [25], which suggests a potential
involvement of GlcCerT and/or GBA2 in the response of
bronchial cells to P. aeruginosa. The non-lysosomal b-glucosidase
GBA2, which is extremely sensitive to deoxynojirimycin-type
inhibitors [34], is a membrane-associated enzyme located in the
plasma membrane and ER of cells [29,35]. GBA2 has been
described as a single pass transmembrane protein with its catalytic
domain facing the extracellular environment [29]. Because this
enzyme can hydrolyze GlcCer directly at the cell surface, it might
be involved in affecting transient local changes in bioactive SL
concentrations.
To gain greater insights into the molecular basis of the anti-
inflammatory activity of miglustat, we explored the potential
involvement of GBA2 in the ceramide-mediated signaling
processes following P. aeruginosa infection of CF bronchial
epithelial cells. The effects of a potent inhibitor of GBA2, N-(5-
adamantane-1-yl-methoxy)pentyl)- deoxynojirimycin or Genz-
529648 as it is referred to in this report [4,36], on the
inflammatory response to P. aeruginosa were investigated and
compared to miglustat and NB-DGJ. We also examined the
impact of lowering the expression of GBA2 in human CF
bronchial epithelial cells exposed to P. aeruginosa using siRNA
oligonucleotides. The results obtained here demonstrate that
GBA2 is a target of the anti-inflammatory effects of miglustat and
Genz-529648. Thus, these compounds provide novel insights into
the role of GBA2 in the signaling cascade activated by P.
aeruginosa in CF bronchial epithelial cells.
Methods
Cell models
IB3-1 (LGC Promochem GmbH, Teddington, Middlesex,
United Kingdom)[37] and CuFi-1 (a generous gift of A.
Klingelhutz, P. Karp and J. Zabner, University of Iowa, Iowa
City)[38] are human bronchial epithelial cells grown as previously
described [24]. Primary airway epithelial cells, i.e., mainstem
human bronchi, derived from CF individuals were obtained from
‘‘Servizio Colture Primarie’’ of the Italian Cystic Fibrosis Research
Foundation and cultured as previously described [39].
Bacterial strains
The reference P. aeruginosa strain, PAO1, was kindly provided
by A. Prince (Columbia University, New York) and grown in
trypticase soy broth (TSB) or agar (TSA) (Difco) as previously
described [25]. Some experiments were conducted with organisms
killed by heating to 65uC for 30 minutes.
Inhibitors of SL metabolism
Miglustat and NB-DGJ were obtained from Toronto Research
Chemicals, North York, ON, Canada. Genz-529648 was obtained
from Genzyme, a Sanofi Company; amitriptyline was obtained
from Sigma.
Inflammatory response in vitro
Cells were treated with different inhibitors or solvent alone and
then infected with PAO1 for 4 hours at 37uC as previously
described [25]. The inflammatory response to PAO1 infection was
studied at the transcriptional level by measuring IL-8 chemokine
expression as previously described [20]. An enzyme-linked
immunosorbent assay for the quantitative measurement of IL-8
protein release was performed using the Human IL-8 Instant
ELISA kit (Bender MedSystems, Vienna, Austria).
Cell toxicity
The effects of Genz-529648 on cell proliferation, viability and
apoptosis were studied to evaluate the potential toxicity as detailed
in the Supplement S3.
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GBA2 silencing
To perform silencing experiments of the GBA2 gene, a
TriFECTa RNAi Kit (Integrated DNA technologies, Coralville,
Iowa, IA) was used. Cells were transiently transfected with specific
siRNA for GBA2 (sequence GGAUCAUGUUUGGAGCUA) or
scrambled (CGUUAAUCGCGUAUAAUACGCGUAT) duplex-
es complexed with cationic liposomes Lipofectamine 2000
(Invitrogen, Carlsbad, CA) diluted in 1 ml serum-free cell culture
medium. GBA2 siRNA or scrambled duplexes (10 nM) were
added and incubated for 10 minutes. Liposome:duplex complexes
(500 mL) were added to the cells grown in 2 cm2 wells and
incubated at 37uC for 6 hours. The cells were washed twice with
culture medium and maintained at 37uC for an additional 18 or
42 hours.
Analysis of cell ceramide content
The analysis of cell ceramide content was performed via two
different approaches: by the LC-MS and LC-MS/MS method
[40] and by the metabolic labeling of cell SLs using (3H)sphin-
gosine as a precursor. Both methods are detailed in the
Supplement S1 and S2.
Enzymatic activity
IB3-1 or CuFi-1 cells were treated with 2 mM miglustat, 10 nM
Genz-529648 or solvent alone for 1 hour and the infected with
heat-killed PAO1 for 4 hours. The cells were then scraped and
centrifuged; the cellular pellets were resuspended in water
containing protease inhibitors and sonicated. After protein
determination, the b-glucosidase activities were assayed in the
total cell lysates using the fluorigenic substrate 4-methylumbelli-
feryl-b-D-glucopyranoside (MUB-Glc) as previously described
[41]. To discriminate between GBA1 and GBA2 b-glucosidase
activity, the enzymatic assays were performed in the presence of
5 nM of Genz-529648 or 500 mM of Conduritol B Epoxide (CBE),
respectively.
Statistics
Results are expressed as the mean 6 standard error of the
mean. Comparisons between groups were made using Student’s t
Figure 1. Genz-529648 reduces P. aeruginosa stimulated IL-8 mRNA expression and protein release. Panels A and B. Genz-529648 reduces
P. aeruginosa stimulated IL-8 mRNA expression. IB3-1 (A) and CuFi-1 (B) cells were treated with a range of doses of Genz-529648 (1–100 nM) or solvent
alone for 1 hour and then infected with PAO1 for 4 hours at 37uC. The inflammatory response was evaluated by studying the expression of IL-8
mRNA, which was measured by Real-time qPCR and obtained by comparing the ratio IL-8 and the housekeeping gene GAPDH between non-infected
and infected cells. The results are expressed as the % of untreated cells and represent the mean 6 standard error of the mean of 4 independent
experiments in duplicate. Comparisons between groups were made by using Student’s t tests. Panels C and D. Genz-529648 reduces the P. aeruginosa
induced IL-8 secretion. IB3-1 (C) and CuFi-1(D) cells were treated with Genz-529648 (100 nM) for 1 hour prior to infection with heat killed PAO1 for 24
hours. Data reported are the mean 6 standard error of the mean of 4 independent experiments in duplicate. Comparisons between groups were
made by using Student’s t tests.
doi:10.1371/journal.pone.0104763.g001
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tests. Statistical significance was defined by p,0.05. In order to
calculate the IC50 values, experimental data were fitted by
nonlinear regression using the software ‘‘R Core Team, 2013,
‘‘R: A language and environment for statistical Computing’’, R
Foundation for Statistical Computing, Vienna, Austria, URL
http://www.R-project.org.
Results
Genz-529648 reduces the expression of IL-8 in CF
bronchial epithelial cells
Several hydrophobic deoxynojirimycin derivatives have been
generated that can be used as research tools to probe the
physiological relevance of GBA2. Complete inhibition of GBA2
can be realized in cells treated with low nanomolar concentrations
of N-(5-adamantane-1-yl-methoxy)pentyl)- deoxynojirimycin
(Genz-529648). GlcCerT and oligosaccharide chain-trimming
glucosidases, which are sensitive to other hydrophobic deoxynojir-
imycin derivatives, are unaffected by Genz-529648 [34]. To
determine a possible involvement of GBA2 in the inflammatory
response to P. aeruginosa in bronchial epithelial cells, the effect of
Genz-529648 was investigated and compared to miglustat and
NB-DGJ. IB3-1 and CuFi-1 cells were treated with increasing
amounts (1–100 nM) of the inhibitors for 1 hour prior to infection
with P. aeruginosa (strain PAO1), and the IL-8 expression was
then analyzed 4 hours post-infection. As shown in panels A and B
in figure 1, Genz-529648 reduced the PAO1 induced increase in
IL-8 mRNA levels by approximately 40% in both cell lines. These
experiments were extended by measuring IL-8 chemokine
secretion in the supernatants of IB3-1 and CuFi-1 cells. Thus,
the cells were treated with Genz-529648 (100 nM) for 1 hour prior
to infection with heat killed PAO1, and the supernatants were
collected 24 hours later. Heat killed organisms were used to
prevent bronchial cell death during the 24 hours of bacterial
challenge. Figure 1, panels C and D, shows that Genz-529648
significantly decreased the amount of IL-8 released from the CF
bronchial cells infected by PAO1 by approximately 30%, which is
consistent with the results obtained at the transcriptional level
(figure 1, panels A and B).
The effects of Genz-529648 in bronchial cells were then
compared to miglustat and NB-DGJ, which also exhibit anti-
inflammatory effects [25]. IB3-1 and CuFi-1 cells were treated
with different concentrations of miglustat, NB-DGJ or Genz-
529648 and infected with PAO1 as previously described; the IL-8
mRNA levels were then measured. As summarized in table 1, a
similar maximal inhibition of approximately 50% was observed in
both cell lines treated with miglustat, NB-DGJ or Genz-529648.
However, the IC50 values of Genz-529648 in IB3-1 and CuFi-1
cells were considerably lower compared to miglustat or NB-DGJ,
which indicated that it is a more potent inhibitor of the
inflammatory response in CF bronchial cells. Moreover, the
IC50 values of Genz-529648 at inhibiting IL-8 expression were of
the same order of magnitude compared to that reported at
inhibiting GBA2 [35], which suggests that the reduction in the
inflammatory response to P. aeruginosa may have been mediated
through its action on GBA2.
Although Genz-529648 is active at nanomolar concentrations,
its potential toxicity on bronchial epithelial cells was investigated.
To determine the impact on cell proliferation, IB3-1 cells were
treated with increasing concentrations of Genz-529648 (from
0.001 to 1 mM), and the cell number/ml was analyzed after 4, 24,
48 and 72 hours. The results, which were derived from three
independent experiments, indicate that the IC50 values calculated
at these time points were always greater than 1 mM, which
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supports the concept that this compound is not cytotoxic at
nanomolar concentrations and does not display inhibitory activity
on CF bronchial cells. Cell viability, which was measured after 4
and 24 hours of treatment (figure S1), was always similar to the
untreated cells and between 91.3 and 97.6%. At the same time
points, treatment with Genz-529648 did not cause apoptotic
effects, even when used at the 1 mM concentration (figures S2 and
S3).
Miglustat and Genz-529648 inhibit GBA2 activity in P.
aeruginosa infected CF bronchial epithelial cells
To ascertain the possible involvement of GBA2 in the signaling
processes associated with P. aeruginosa infection, total b-
glucosidase, GBA1 and GBA2 activities in the lysates of both
IB3-1 and CuFi-1 cells infected by heat killed PAO1 were
measured. To prevent potential interference because of bacterial
glucosidase activities, the infected cells were subjected to washes
with PBS that removed most bacteria; moreover, heat killed
instead of living organisms were used. In addition, the residual
GBA1 and GBA2 activities associated with heat killed bacteria
were measured by enzymatic assays on the amounts of heat killed
PAO1 from 20 to 30-fold higher compared to those used for the
cell infection. The fluorescence associated with the PAO1 samples,
which was the result of hydrolysis of the artificial substrate MUB-
Glc, was less or the same extent of that identified in the negative
controls, which indicates that heat killed PAO1 does not have
detectable b-glucosidase activity. As shown in figure 2, a
significant increase in total b-glucosidase (figure 2, panel A),
GBA1 (figure 2, panel B) and GBA2 (figure 2, panel C) activities
were observed in response to infection. The effects of pre-
treatment with miglustat or Genz-529648 on b-glucosidase activity
were then studied in both IB3-1 and CuFi-1 cells infected with
PAO1. Total b-glucosidase was slightly reduced in both cell lines
treated with the two inhibitors (figure 3, panel A), whereas GBA1
activity remained unchanged (figure 3, panel B). Importantly, both
miglustat and Genz-529648 significantly decreased GBA2 activity
in bronchial cells infected with P. aeruginosa (figure 3, panel C).
These results demonstrate that miglustat and Genz-529648
inhibited the activity of GBA2 and support the hypothesis that
GBA2 could be a target of the anti-inflammatory effects of
deoxynojirimycin-type inhibitors.
Figure 2. Infection with PAO1 increases b-glucosidase activity in IB3-1 and CuFi-1 cells. IB3-1 and CuFi-1 cells were infected with heat-
killed PAO1 for 4 hours. The cells were then scraped and centrifuged; the cellular pellets were resuspended in water containing protease inhibitors
and sonicated. Similar amounts of cellular proteins were used to perform the enzymatic assays to detect the activities of total b-glucosidase (A), GBA1
(B) and GBA2 (C), as reported in the Methods section. The data reported are the mean 6 standard error of the mean of 4 (IB3-1) or 3 (CuFi-1)
independent experiments in triplicate. Comparisons between groups were made by using Student’s t tests.
doi:10.1371/journal.pone.0104763.g002
Figure 3. Miglustat and Genz-529648 inhibit GBA2 activity in IB3-1 and CuFi-1 cells infected by P. aeruginosa. IB3-1 and CuFi-1 cells
were treated with [2 mM] miglustat, [10 nM] Genz-529648 or solvent alone for 1 hour prior to infection with heat-killed PAO1 for 4 hours. Total b–
glucosidase (A), GBA1 (B) and GBA2 (C) activities were measured as indicated in figure 2. The data reported are the mean 6 standard error of the
mean of 3 (IB3-1) or 2 (CuFi-1) independent experiments in triplicate. Comparisons between groups were made by using Student’s t tests.
doi:10.1371/journal.pone.0104763.g003
Role of GBA2 in P. aeruginosa Infected CF Cells
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siRNA-mediated silencing of GBA2 in CF bronchial cells
decreases IL-8 expression
To confirm if GBA2 is involved in the signaling cascade
activated by P. aeruginosa infection of CF bronchial cells, the
levels of IL-8 were measured following GBA2 silencing with
siRNA oligonucleotides. The cells were transiently transfected with
a siRNA that specifically targeted the degradation of human
GBA2 mRNA or a control duplex scrambled siRNA. As shown in
figure 4, panel A, transfection of IB3-1 cells with the GBA2-
specific siRNA significantly reduced (30%) the level of expression
of GBA2 mRNA. Transfection of CuFi-1 cells with the GBA2
siRNA produced a greater decrease (60%) in GBA2 mRNA levels
(figure 4, panel B). The experiments were then repeated in
primary CF bronchial cells, a cell model that closely resembles the
native epithelium, where a decrease of GBA2 expression (,60%)
was also identified after transfection with the GBA2 specific siRNA
(figure 4, panel C). As shown in figure 5, the silencing of GBA2
expression decreased IL-8 transcription in both uninfected cells
(figure 5, panels A, B and C) and cells infected by P. aeruginosa
(figure 5, panels D, E and F); however, in IB3-1 cells, the IL-8
reduction was not significant (figure 5, panels A and D). These
findings were confirmed by measuring IL-8 protein levels in the
supernatants of CuFi-1 cells at 4 hours post-infection with PAO1.
As expected, the decrease in IL-8 mRNA expression was
accompanied by a significant reduction in the secretion of IL-8
into the supernatant (figure 6). To provide evidence that the
reduction of IL-8 levels is related to a decrease in GBA2 function,
GBA2 activity was measured in GBA2 silenced CuFi-1 cells.
Therefore, the cells were transiently transfected as previously
described, and the total b-glucosidase and GBA2 activities in cell
lysates were measured 18 and 42 hours after transfection. As
shown in figure 7, panel A, GBA2 activity was significantly
decreased at 18 hours after transfection. A further reduction of
GBA2 activity resulted from measurements performed 42 hours
after silencing. In these experimental conditions, transfection with
siRNA that targeted GBA2 had an impact only on GBA2 activity,
as demonstrated by the slight decrease of total b-glucosidase
activity identified in GBA2 silenced cells (figure 7, panel B). These
data, which demonstrate that lowering the expression and activity
of GBA2 leads to a concomitant reduction in IL-8 levels, suggest a
role for GBA2 in the inflammatory response induced by P.
aeruginosa infection of CF bronchial cells.
Increase of cell ceramide content induced by
P. aeruginosa in CF bronchial cells
Inhibiting the catabolism of GlcCer by GBA2 could also lower
ceramide levels and thereby reduce pulmonary inflammation in
CF patients. We have previously shown that miglustat reduced the
expression of immunoreactive ceramides (measured by immuno-
fluorescence) induced by P. aeruginosa [20]. To assess the effect of
P. aeruginosa infection on the total cell ceramide content, LC-MS
and LC-MS/MS analyses were performed as detailed in the
Supplement S1. In the PAO1 infected IB3-1 and CuFi-1 cells, a
significant increase in ceramides was identified (figure 8, panels A
and B), which indicated that the infection up-modulated whole cell
ceramide levels. Treatment with miglustat or Genz-529648
significantly reduced whole cell ceramide in IB3-1 cells by
approximately 50% (figure 8, panel A), whereas in CuFi-1 cells,
a small, albeit not significant decrease in ceramide levels was
identified (figure 8, panel B).
To better evaluate the contribution of GSL catabolism to the
ceramide increase following PAO1 infection, cell SL metabolic
labeling was performed with the radioactive precursor sphingo-
sine, which enables labeling of SLs at the steady-state. Thus, the
effects of drug treatment on the radioactive ceramide content are
only because of the modulation of the SL catabolism, thereby
excluding the de novo pathway. To discriminate between the
ceramide derived from SM catabolism and GSLs, we treated cells
with amitriptyline alone, which is an inhibitor of ASM activity, or
in combination with Genz-529648. IB3-1 and CuFi-1 cells were
also subjected to the SL metabolic labeling with (1-3H) sphingosine
and were then differently treated with 10 mM amitriptyline alone
or in combination with 10 nM Genz-529648 and infected with
PAO1 as detailed in the Supplement S2. The total lipid extracts
(ELT) obtained from cells were subjected to HPTLC separation to
distinguish ceramide from the other SLs. The radioactive
ceramide was quantified by digital autoradiography (figure 9,
panel A). In the CuFi-1 cells, the ceramide levels were under the
Figure 4. Transfection with GBA2 siRNA reduces the expression of GBA2 in CF bronchial cells. IB3-1 (A), CuFi-1 (B) or CF primary
bronchial cells (C) were transfected with GBA2 siRNA or scrambled oligonucleotides for 24 h. GBA2 mRNA expression was measured by Real-time
qPCR and obtained by comparing the ratio GBA2 and the housekeeping gene GAPDH between scrambled or siRNA treated cells. The data reported
on the y-axis are relative to scrambled-treated cells and represent the mean 6 SE of five (IB3-1, panel A), eight (CuFi-1, panel B) and four (CF primary
bronchial, panel C) independent experiments performed in duplicate. Comparisons between groups were made by using Student’s t tests.
doi:10.1371/journal.pone.0104763.g004
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sensitivity threshold of the digital autoradiograph used. By
contrast, a significant increase in the ceramide content after
PAO1 infection was observed in the IB3-1 cells. The treatment of
cells with amitriptyline caused a slight reduction of ceramide,
whereas a significant decrease of the ceramide content was
observed when infected cells were treated with both amitriptyline
and Genz-529648; these findings support a direct involvement of
GBA2 in ceramide production (figure 9, panel B).
Discussion
Recent advances in glycobiology have encouraged a search for
novel drug molecules that address new biochemical targets.
Iminosugars, which are carbohydrate-mimetics with a nitrogen
atom replacing oxygen, have many attributes that make them
suitable as small-molecule drug candidates. Pharmaceutical
interest in these compounds is related to their ability to modulate
carbohydrate processing, control cancer cell glycosylation, reduce
viral and bacterial infectivity, alter immune responses and bind
carbohydrate receptors [22]. The iminosugar miglustat, which was
approved to treat type I Gaucher disease and Niemann-Pick type
C disease, exerts an anti-inflammatory effect in CF human
bronchial epithelial cells infected by P. aeruginosa and down
modulates the neutrophil chemotaxis in murine lungs in vivo
[20,23]. Here, we report that the non-lysosomal b-glucosidase 2, is
a target of the anti-inflammatory effects of miglustat and other
deoxynojirimycin-type inhibitors used in this study. This conten-
tion is supported by the findings that: i) treatment of P. aeruginosa
infected CF bronchial cells with Genz-529648, a potent inhibitor
of GBA2, reduced the extent of inflammation; ii) the IC50 value of
the anti-inflammatory effect of Genz-529648 was similar com-
pared to the effect reported toward inhibiting GBA2 activity (33);
iii) treatment of CF bronchial cells with miglustat or Genz-529648
inhibited GBA2; and iv) inhibition of GBA2 by siRNA lowered
the expression of IL-8.
The alkylated iminosugars miglustat, NB-DGJ and Genz-
529648 employed in this study inhibit GlcCerT, GBA1 and
GBA2. However, the impact of these compounds on GlcCerT and
GBA activities depends greatly on their dosage [30]. Lower
concentrations of iminosugars primarily affect GBA2, whereas
higher doses inhibit all enzymes. Notably, we obtained a reduction
of P. aeruginosa stimulated IL-8 mRNA expression in CF
bronchial cells treated with Genz-529648 at very low nanomolar
Figure 5. Reduction of IL-8 is associated with a relevant decrease of GBA2 expression in CF bronchial cells. IB3-1 (A), CuFi-1 (B) or CF
primary bronchial cells (C) were transfected with GBA2 siRNA or scrambled oligonucleotides for 24 h and then infected with PAO1 (10–50 CFU/cell).
IL-8 mRNA expression was measured as indicated in figure 1. The data reported on the y-axis are relative to scrambled-treated cells (A, B and C) or
scrambled-treated uninfected cells (D, E and F) and represent the mean6 SE of five (IB3-1, panels A and D), eight (CuFi-1, panels B and E) and four (CF
primary bronchial, panels C and F) independent experiments performed in duplicate. Comparisons between groups were made by using Student’s t
tests.
doi:10.1371/journal.pone.0104763.g005
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concentrations, which completely inhibited GBA2 activity, but not
GBA1 or GlcCerT [34]. Measurements of the sensitivity of
GlcCerT, GBA1 and GBA2 to the inhibition by miglustat in
different mammalian cells/tissues revealed IC50 values in the low
mM, high mM and nM range, respectively. This finding indicates
that GBA2 is more sensitive to miglustat compared to GlcCerT
and GBA1 [30]. Although the IC50 values of miglustat at
inhibiting P. aeruginosa stimulated IL-8 mRNA expression in
CF bronchial cells (table 1) are higher compared to the IC50 values
for inhibiting GBA2, they are substantially lower compared to
GlcCerT and GBA1. Hence, GlcCerT and GBA1 are unlikely to
have been the targets of the anti-inflammatory effects of miglustat.
Furthermore, we previously reported that miglustat down mod-
ulates neutrophil chemotaxis in vivo at doses that are lower
(100 mg/Kg) [20] compared to the doses necessary to affect
GlcCerT (1800–2400 mg/Kg) [42], which further supports the
notion that the primary effect of miglustat is on GBA2 activity.
GBA2 plays a role in extra-lysosomal GlcCer catabolism,
producing ceramide that can then be rapidly converted into
sphingomyelin [29]. Although the mechanism and function of
extra-lysosomal GlcCer degradation are not well understood,
GBA2 has recently been implicated in various pathologic
conditions, such as neuronal diseases [43] or cancer [44], which
supports a role of GlcCer in cell growth, proliferation and
immunity. The present novel findings suggest that GBA2 may also
be involved in modulating the inflammatory response to P.
aeruginosa infection in CF bronchial epithelial cells. Indeed, total
b-glucosidase, GBA1 and GBA2 activities were elevated in CF
bronchial cells infected by P. aeruginosa (figure 2). As for the
effects of infection on SLs, it should be noted that infection of host
epithelial cells with P. aeruginosa activates host ASM levels, which
leads to the generation of plasma membrane ceramide-enriched
platforms that promote the internalization of bacteria, induce
apoptosis and regulate the cytokine storm [13]. Based on the
observations noted in our studies, it is possible that in addition to
ASM, an overall activation of b-glucosidase activity may also be
involved in the host cell response to infection. However, additional
studies are needed to validate this assumption. Importantly,
miglustat or Genz-529648, at the concentrations used in this study,
strongly inhibited only GBA2 activity (figure 3); in parallel, we
demonstrated a reduction of P. aeruginosa stimulated IL-8 mRNA
expression and protein release in CF bronchial cells when GBA2
expression (figure 5) and function (figures 1 and 7) were decreased.
These findings support the contention that GBA2 is involved in
the inflammatory response to P. aeruginosa. GBA2 is typically
associated with plasma- and/or ER-membranes in close proximity
to the sites of GlcCer synthesis and ceramide conversion to SM
[45]. Therefore, as GBA2 is in a key position for GlcCer-mediated
signaling, it could be activated following interactions between P.
aeruginosa and the host cell. It has been shown that GBA2
activation causes the phosphorylation of eukaryotic initiation
factor 2a (eIF2a), and this event is associated with an increased
expression of the ATF4 family of transcription factors [44].
Interestingly, phosphorylation of eIF2a has been observed in
models of acute infection with Clostridium difficile, as part of the
mucosal inflammatory response [46]. It can be speculated that
GBA2 activation by P. aeruginosa leads to increased expression of
the transcription factors that regulate the pro-inflammatory genes
in CF bronchial cells.
The airway epithelium is known to play a key role in the
initiation and regulation of inflammatory processes in response to
pathogens. In addition to the classical cytokines and chemokines
that are released by the respiratory epithelium, ceramide is
another important factor in pulmonary host defense [11]. Here,
we report an increase in whole cell ceramides in response to
infection by P. aeruginosa (figures 8 and 9) in CF bronchial
Figure 6. GBA2 silencing reduces the IL-8 protein release in CuFi-1 cells. CuFi-1 cells were transfected with GBA2 siRNA or scrambled
oligonucleotides and then infected with PAO1 as indicated in figure 5. The supernatants were collected at the end of infection, and IL-8 protein
release was measured as detailed in the ‘‘Methods’’ section. The data reported are the mean 6 SE of eight independent experiments performed in
duplicate. Comparisons between groups were made by using Student’s t tests.
doi:10.1371/journal.pone.0104763.g006
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Figure 7. GBA2 silencing reduces GBA2 activity in CuFi-1 cells. CuFi-1 cells were transfected with GBA2 siRNA or scrambled oligonucleotides
as indicated in figure 5. Eighteen or 42 hours after transfection, the cells were scraped and treated as indicated in figure 2. Total b-glucosidase (B) and
GBA2 (A) activities were measured as reported in the Methods section. The data reported are the mean 6 standard error of the mean of 2
independent experiments in triplicate. Comparisons between groups were made by using Student’s t tests.
doi:10.1371/journal.pone.0104763.g007
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epithelial cells, which is consistent with the rise of ceramide levels
at the plasma membrane previously described [20]. In CuFi-1
cells, which have a lower ceramide content compared to IB3-1
cells, we observed a slight decrease in ceramide levels by miglustat
or Genz-529648 (figure 8, panel B). By contrast, IB3-1 cells
infected with PAO1 and treated with both miglustat and Genz-
Figure 8. Infection with PAO1 increases whole cell ceramides in CF bronchial epithelial cells. IB3-1 (A) and CuFi-1 (B) cells were treated
with [2 mM] miglustat, [10 nM] Genz-529648 or solvent alone and infected with PAO1 as indicated in figure 3. After infection, whole cell ceramides
were analyzed by LC-MS and LC-MS/MS methods as described in the online supplement. The data reported are the mean 6 SE of three independent
experiments performed with both cell lines. Comparisons between groups were made by using Student’s t tests.
doi:10.1371/journal.pone.0104763.g008
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Figure 9. Treatment with Genz-529648 reduces the ceramide content in IB3-1 cells infected with PAO1. IB3-1 cells subjected to the SL
metabolic labeling with (1-3H)sphingosine were treated with [10 mM] amitriptyline alone, in combination with [10 nM] Genz-529648, or with solvent
alone and infected with PAO1 as indicated in figure 3. After lipid extraction, (3H)ceramide was separated from the other radioactive SLs by HPTLC, as
detailed in the online supplement, and detected by digital autoradiography (total lipid extracts amounts corresponding to 4 mg of cellular proteins
were applied on a 4-mm line. Time of acquisition: 48 hours). The digital autoradiography represents data obtained in three different experiments (A).
The ceramide content was quantified by specific b-Vision software, and the data reported are the mean 6 SE of three independent experiments.
Comparisons between groups were made by using Student’s t tests (B).
doi:10.1371/journal.pone.0104763.g009
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529648 showed a marked decrease of ceramide content (figure 8,
panel A). The increase in ceramide content following infection by
PAO1 could be a result of different pathways, including the de
novo biosynthesis [21], SM catabolism [13] and GSL degradation.
When we evaluated the effects of drug treatment on the
radioactive ceramide content that resulted only because of the
modulation of SL catabolism, thus excluding the de novo pathway,
we identified a marked increase in the cell ceramide content after
PAO1 infection (figure 9). After ASM inhibition, we observed a
slight decrease and a further, more significant ceramide reduction
after the addition of the specific inhibitor of GBA2, Genz-529648
(figure 9), which strongly supports the direct involvement of GBA2
in the ceramide production after PAO1 infection of human
bronchial epithelial cells. Thus, the information derived from the
literature and the data presented here provide evidence that
different inhibitors, such as miglustat and Genz-529648, amitrip-
tyline [14] and myriocin [21], that target GBA2, ASM and
ceramide de novo synthesis, respectively, could represent thera-
peutic tools to reduce ceramide levels and limit excessive lung
inflammation in CF patients (figure 10). Nevertheless, drugs that
target SL metabolism must be carefully titrated to normalize
ceramide levels in CF airways, but not reduce ceramide
concentrations below a critical level that would impair normal
biological functions. Notably, systemic inhibition of ASM could
negatively affect the host defense, which has been demonstrated by
studies in mice that completely lack ASM and are unable to
control infections [13]. Interestingly, no increased susceptibility to
bacterial infections has been identified in patients affected by
Gaucher disease, treated with miglustat [47] or in a mouse model
of Sandhoff disease treated with Genz-529648 [48].
In summary, our study proposes GBA2 as a novel target to
reduce the inflammatory response to P. aeruginosa in CF
bronchial cells. These results further support the use of modulators
of SL metabolism for CF lung inflammation. In addition, as GBA2
is sensitive to very low doses of miglustat, other alkylated
iminosugars (NB-DGJ) and Genz-529648, our findings provide
evidence to develop therapeutic options for CF lung inflammation
using iminosugars, which can be effective at even low doses, thus
limiting potential adverse effects.
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Figure S1 Viability profile of IB3-1 cells treated for 24
hours with the indicated concentrations of Genz-529648.
(TIF)
Figure S2 Apoptosis profile of IB3-1 cells treated for 24
hours with the indicated concentration of Genz-529648.
(TIF)
Figure S3 Apoptotic IB3-1 cells after 4 and 24 hours of
treatment with the indicated concentrations of Genz-
529648.
(TIF)
Supplement S1 Analysis of cell ceramide levels using
LC-MS and LC-MS/MS.
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Figure 10. Metabolic pathways involved in ceramide formation. Schematic representation of the primary metabolic pathways involved in
ceramide production. Ceramide can be produced by the de novo biosynthesis, the hydrolysis of sphingomyelin (SM) by the action of
sphingomyelinases and the catabolism of glycosphingolipids (GSL). In particular, it has been observed that in CF bronchial epithelial cells, the use of
inhibitors of these pathways resulted in a reduction of ceramide. Myriocin acts on the first step of the de novo biosynthesis through the inhibition of
the Serine-palmitoyl transferase (SPT); amitriptyline inhibits the acid SMase (ASM) responsible for SM catabolism; and miglustat, NB-DGJ and Genz-
529648 are inhibitors of the b-glucosidases GBA1 and GBA2, which are involved in the hydrolysis of the glucosylceramide (GlcCer).
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